Critical Care: Critical Care: ARDS/ALI |

Predictive Value of Plasma Galectin-3 for ARDS Severity and Patient Outcome FREE TO VIEW

Zhiheng Xu, MD; Yongbo Huang, PhD; Pu Mao, PhD; Ying Pan, MD; Jianchun Li, MD; Yimin Li, PhD
Author and Funding Information

State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A159. doi:10.1016/j.chest.2016.02.165
Text Size: A A A
Published online


SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Acute respiratory distress syndrome (ARDS) is characterized by lung fibrosis which often leads to serious mortality. We sought to determine whether high level of the novel fibrosis biomarker galectin-3 (Gal-3) is associated with the severity of ARDS and poor outcomes.

METHODS: Patients, who were administrated into ICU of Guangzhou Medical University 1st Affiliated Hospital within 48 hours and diagnosed as ARDS, were identified from October 2012 to March 2015. Besides, 20 consecutive healthy people were assigned to control group. The plasma galectin-3 level of each patient was measured by ELISA with the collected blood sample. The primary outcome was ICU 28-day mortality.

RESULTS: Total of 63 ARDS patients had been identified. Among them, 27 had been dead within 28-day follow-up. The plasma galectin- 3 level of them was significantly higher than control group (median (IQR) 12.37 (7.94-18.79) versus 5.01 (4.15-5.69) ng/mL, P< 0.0001). Furthermore, it was significantly higher in nonsurvivors group than others (10.07 (7.39-15.54) vs. 15.38 (11.59-22.98) ng/mL, P = 0.0136). The level of galectin-3 was correlated to the severity of ARDS (P<0.0001). Correlation analysis showed that the levels of plasma galectin-3 were significantly correlated with APACHEⅡ score and PaO2/FiO2 ratio (Spearman’s rho = 0.44 and -0.616, respectively, P<0.0001). At an optimal cutoff of 10.58ng/mL, the sensitivity and specificity of galectin-3 for ICU 28-day mortality prediction were 81.48% (95% CI 61.9%, 93.6%) and 55.56% (95% CI 38.1%, 72.1%), respectively.

CONCLUSIONS: This study shouws that higher level of galectin-3 is significantly associated with severer disease and worse outcome in ARDS patients.

CLINICAL IMPLICATIONS: Measurement of circulating galectin-3 may improve the diagnostic and prognostic accuracy of patients with ARDS. However, the pathophysiological mechanisms of it remains unclear. Further studies are necessary to fill the gap of our knowledge.

DISCLOSURE: The following authors have nothing to disclose: Zhiheng Xu, Yongbo Huang, Pu Mao, Ying Pan, Jianchun Li, Yimin Li

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543